Lead Product(s): FB825
Therapeutic Area: Dermatology
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Leo Pharma
Deal Size: $570.0 million Upfront Cash: $40.0 million
Deal Type: Licensing Agreement April 15, 2020
Oneness will be responsible for executing the Phase 2a study for Atopic Dermatitis in the United States and Microbio Shanghai will execute the Phase 2a study for allergic asthma in China.